FDA Approves Gilead’s COVID-19 Drug for Young Children

The US drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences's drug remdesivir.
Reuters Health Information
The US drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences’s drug remdesivir.
Reuters Health Information